Showing results (71-80 of 83) with videos related to
Sort By:
Pageof 9
European Journal of Medicinal Chemistry|July 28, 2018
Discovery of (S)-2-amino-N-(5-(6-chloro-5-(3-methylphenylsulfonamido)pyridin-3-yl)-4-methylthiazol-2-yl)-3-methylbutanamide (CHMFL-PI3KD-317) as a potent and selective phosphoinositide 3-kinase delta (PI3Kδ) inhibitorXiaofei Liang, Feng Li, Cheng Chen, et al.European Journal of Pharmacology|February 13, 2021
Discovery of a highly potent kinase inhibitor capable of overcoming multiple imatinib-resistant ABL mutants for chronic myeloid leukemia (CML)Tingting Lu, Jiangyan Cao, Fengming Zou, et al.Journal of Medicinal Chemistry|June 29, 2019
Discovery of 2-(4-Chloro-3-(trifluoromethyl)phenyl)-<i>N</i>-(4-((6,7-dimethoxyquinolin-4-yl)oxy)phenyl)acetamide (CHMFL-KIT-64) as a Novel Orally Available Potent Inhibitor against Broad-Spectrum Mutants of c-KIT Kinase for Gastrointestinal Stromal TumorsYun Wu, Beilei Wang, Junjie Wang, et al.Investigational New Drugs|December 25, 2019
Discovery of a novel and highly selective CDK9 kinase inhibitor (JSH-009) with potent antitumor efficacy in preclinical acute myeloid leukemia modelsLi Wang, Chen Hu, Aoli Wang, et al.Journal of Medicinal Chemistry|May 4, 2019
Discovery of ( E)- N<sup>1</sup>-(3-Fluorophenyl)- N<sup>3</sup>-(3-(2-(pyridin-2-yl)vinyl)-1 H-indazol-6-yl)malonamide (CHMFL-KIT-033) as a Novel c-KIT T670I Mutant Selective Kinase Inhibitor for Gastrointestinal Stromal Tumors (GISTs)Xuesong Liu, Beilei Wang, Cheng Chen, et al.Cancer Biology & Therapy|March 22, 2019
Discovery and characterization of a novel highly potent and selective type II native and drug-resistant V299L mutant BCR-ABL inhibitor (CHMFL-ABL-039) for Chronic Myeloid Leukemia (CML)Jiaxin Wu, Aoli Wang, Xixiang Li, et al.Journal of Medicinal Chemistry|December 20, 2018
Discovery of N-(4-(6-Acetamidopyrimidin-4-yloxy)phenyl)-2-(2-(trifluoromethyl)phenyl)acetamide (CHMFL-FLT3-335) as a Potent FMS-like Tyrosine Kinase 3 Internal Tandem Duplication (FLT3-ITD) Mutant Selective Inhibitor for Acute Myeloid LeukemiaXiaofei Liang, Beilei Wang, Cheng Chen, et al.European Journal of Medicinal Chemistry|September 26, 2018
Discovery of 4-(((4-(5-chloro-2-(((1s,4s)-4-((2-methoxyethyl)amino)cyclohexyl)amino)pyridin-4-yl)thiazol-2-yl)amino)methyl)tetrahydro-2H-pyran-4-carbonitrile (JSH-150) as a novel highly selective and potent CDK9 kinase inhibitorBeilei Wang, Jiaxin Wu, Yun Wu, et al.European Journal of Medicinal Chemistry|October 15, 2018
Discovery of (E)-N-(4-((4-methylpiperazin-1-yl)methyl)-3-(trifluoromethyl)phenyl)-3-((3-(2-(pyridin-2-yl)vinyl)-1H-indazol-6-yl)thio)propanamide (CHMFL-ABL-121) as a highly potent ABL kinase inhibitor capable of overcoming a variety of ABL mutants including T315I for chronic myeloid leukemiaXuesong Liu, Beilei Wang, Cheng Chen, et al.Journal of Medicinal Chemistry|September 29, 2017
Discovery of 1-(4-(4-Amino-3-(4-(2-morpholinoethoxy)phenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)phenyl)-3-(5-(tert-butyl)isoxazol-3-yl)urea (CHMFL-FLT3-213) as a Highly Potent Type II FLT3 Kinase Inhibitor Capable of Overcoming a Variety of FLT3 Kinase Mutants in FLT3-ITD Positive AMLAoli Wang, Xixiang Li, Cheng Chen, et al.Pageof 9